{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-003205","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.227237+00:00","generated_at":"2026-06-27T00:04:39.393604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immuneering reports $150.2M cash; IND for IMM-1-104 expected Q3 2022","bullets":["Net loss Q4 2021: $10.8M ($0.42/share) vs $5.8M ($1.18/share) Q4 2020; full year loss $33.5M.","Cash and equivalents $150.2M as of Dec 31, 2021; expected cash runway into Q3 2024.","2022 GAAP operating expense guidance $55M-$60M; includes non-cash stock-based compensation.","IMM-1-104 IND filing expected Q3 2022, first patient enrollment in Phase 1 trial Q4 2022.","IMM-6-415 designated as drug candidate; IND-enabling studies underway, filing expected 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-003205","json":"https://secwatch.observer/filing/0001558370-22-003205.json","markdown":"https://secwatch.observer/filing/0001558370-22-003205.md","text":"https://secwatch.observer/filing/0001558370-22-003205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/0001558370-22-003205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/imrx-20220310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:04:39.393604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}